Andrew Madin

USPTO Granted Patents = 52 (Patent Applications = 2)

EPO Patents = 21 (Patent Applications = 16)

Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 255(Granted Patents)

Forward Citations (Not Self Cited) = 227(Oct 12, 2025)

Location History:

Sawbridgeworth, GB (1998 - 2009)
Harlow, GB (2003 - 2024)
Cambridge, GB (2011 - 2024)
Bishop's Stortford, GB (2018 - 2024)

Company Filing History:

25 out of 2,405

Merck Sharp + Dohme Corp.

patents

14 out of 31

Mission Therapeutics Limited

Astex Therapeutics Limited

patents

5. 1 out of 76

Merck Frosst Canada & Co.

patents

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...

52 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

2. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

3. 12208088 - Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof (2025-01-28),

4. 11993595 - Compounds (2024-05-28),

5. 11958833 - Compounds (2024-04-16),

6. 11944606 - Azaindoles as inhibitors of HPK1 (2024-04-02),

7. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

8. 11472798 - Compounds (2022-10-18),

9. 11414402 - Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors (2022-08-16),

10. 11370784 - Cyano-substituted heterocycles with activity as inhibitors of USP30 (2022-06-28),

11. 11130748 - Compounds (2021-09-28),

12. 11091488 - 1-cyano-pyrrolidine derivatives as inhibitors of USP30 (2021-08-17),

13. 11084821 - Cyanopyrrolidine derivatives with activity as inhibitors of USP30 (2021-08-10),

14. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

15. 11014912 - Cyanopyrrolidine derivatives with activity as inhibitors of USP30 (2021-05-25),

Title: Innovator Spotlight: Andrew Madin

Introduction

Andrew Madin, a prolific inventor based in Cambridge, GB, has made significant contributions to the field of medicinal chemistry. With an impressive portfolio of 50 patents, his work primarily focuses on the development of novel compounds and therapeutic methods.

Latest Patents

Among Andrew’s latest patents is a groundbreaking exploration of spirocyclic 2,3-dihydro-7-azaindole compounds. These compounds are reported to be effective as inhibitors of HPK1 (hematopoietic kinase 1), a critical component in treating HPK1-dependent disorders. They are also valuable in enhancing immune responses. The patent details methods of inhibiting HPK1, treating relevant disorders, boosting immune responses, and preparing these innovative compounds. Additionally, Andrew's patent portfolio includes the development of new compounds aimed at inhibiting deubiquitylating enzymes (DUBs), specifically targeting ubiquitin C-terminal hydrolase L1 (UCHL1). These DUB inhibitors show promise in the treatment of cancer and other health conditions, showcasing his commitment to advancing medical science.

Career Highlights

Andrew has held notable positions in renowned companies, including Merck Sharp & Dohme Corporation and Mission Therapeutics Limited. His experience at these organizations has equipped him with valuable insights and expertise in drug development and innovation.

Collaborations

Throughout his career, Andrew has collaborated with several esteemed colleagues, including Martin Stockley and Timothy Harrison. These partnerships have fostered an environment of creativity and innovation, leading to numerous advancements in his research and patent portfolio.

Conclusion

Andrew Madin exemplifies the spirit of innovation in the pharmaceutical industry. His extensive patent portfolio and collaborative efforts are a testament to his dedication to improving healthcare through scientific research and discovery. As he continues to explore new frontiers in medicinal chemistry, his work remains crucial to the development of effective therapies and treatments.

This text is generated by artificial intelligence and may not be accurate.